INV-043 sublingual / Invion - LARVOL DELTA

Invion Limited (ASX:IVX) Prostate Cancer Trial Results (ABN Newswire) - P2 | N=50 | ACTRN12621000633886 | "The trial results showed that INV043 administered sublingually (under the tongue) has a solid safety profile and demonstrated promising efficacy signals three months post treatment: A regime of 6 cycles of INV043 treatments was very well tolerated by patients; No serious adverse events were experienced and all side effects reported were mild; 40% of patients showed a positive response as measured by the RECIST 1.1 standard (10% had complete response); 44% of patients had negative PSMA-PET results 3 months post treatment."

P2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor